tradingkey.logo
tradingkey.logo
Search

Acumen Pharmaceuticals Completes Enrollment Of Altitude-Ad, A Phase 2 Clinical Trial Of Sabirnetug (Acu193) In Early Alzheimer’S Disease

ReutersMar 26, 2025 12:07 PM
facebooktwitterlinkedin

- Acumen Pharmaceuticals Inc ABOS.O:

  • ACUMEN PHARMACEUTICALS COMPLETES ENROLLMENT OF ALTITUDE-AD, A PHASE 2 CLINICAL TRIAL OF SABIRNETUG (ACU193) IN EARLY ALZHEIMER’S DISEASE

  • ACUMEN PHARMACEUTICALS INC - TOPLINE RESULTS EXPECTED IN LATE 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI